Immunotherapy: Unlocking New Ways to Fight Cancer
Learning of a cancer diagnosis has commonly brought with it not only fears for one’s health and one’s life, but the knowledge that the path to successful treatment was by no means easy or risk free. Most chemotherapy and radiation treatments come at a high expense to the patient’s body—harming healthy cells right along with malicious cancer cells and putting patients at risk for other cancers or even other disease or health problems. While in the best circumstances the end result is permanent elimination of cancer, in too many instances a few cancer cells survive and lead to relapse. Immunotherapy offers the potential to allow the body to kill the remaining resistant tumor cells.
New combination therapy developed for multiple myeloma
Each year, more than 25,000 Americans are diagnosed with multiple myeloma, a form of blood cancer that often develops resistance to therapies. However, researchers at Virginia Commonwealth University Massey Cancer Center are reporting promising results from laboratory experiments testing a new combination therapy that could potentially overcome the resistance hurdle.
Annual Massey Research Retreat draws record turnout
On Friday, May 23, the annual Virginia Commonwealth University (VCU) Massey Cancer Center Research Retreat attracted more than 150 attendees to learn about the most promising cancer research being conducted at Massey and throughout VCU.
New combination therapy eradicates prostate cancer in vivo
In their study, published in the journal Proceedings of the National Academy of Sciences, prostate cancer growth in mice with functioning immune systems was inhibited by sensitizing the cancer cells with the drug Sabutoclax (BI-97C1) and using UTMD technology to deliver a viral gene therapy that expresses the genemda-7/IL-24. This powerful new approach to treating prostate cancer builds upon prior studies by principle investigator Paul B. Fisher, M.P.H., Ph.D., Thelma Newmeyer Corman Endowed Chair in Oncology Research at VCU Massey (photo on left). Fisher is professor and chair of the Department of Human and Molecular Genetics in the VCU School of Medicine, and director of the VCU Institute of Molecular Medicine.
Doctoral student crosses disciplines to develop a new therapy for pancreatic cancer
David Durrant is a doctoral candidate in the Department of Biochemistry and Molecular Biology at the VCU School of Medicine. With guidance from Rakesh Kukreja, M.S., Ph.D., he is making significant progress testing a new combination therapy for pancreatic cancer, and many in the field of pharmacology are taking notice.